US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness

Uppsala, Sweden – 17 February 2026   Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment. In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance BEA-17, Beactica’s wholly owned, first-in-class degrader of the epigenetic protein complex LSD1–

Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17

Beactica Therapeutics AB, the Swedish precision medicine company, today announced that it has conducted a first scientific advisory meeting with the Swedish Medical Products Agency regarding the drug candidate BEA-17. Specifically, the company's plans for the preclinical development aimed at enabling dosing of BEA-17 in humans were discussed. The Swedish Medical Products Agency expressed its support for Beactica's plans. Positive discussions were also held regarding the design and setup of a first clinical trial with BEA-17. "It is an important milestone for BEA-17 and Beactica to have

Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024

Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024. The conference will take place on April 5–10, 2024 in San Diego, California.Dr Peter Brandt, Head of Chemistry, will present a poster entitled Degraders of TEAD transcription factors based on interface 3 binders on Sunday April 7, 2024, at 1:30 PM – 5:00 PM. The location is at the San Diego Convention Center, Section 52, abstract presentation number: LB029. The

Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences

Beactica Therapeutics AB, the Swedish precision oncology company, today announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers at the U.S. National Institutes of Health (NIH). The collaboration will focus on the translation of novel proteolysis-targeting degraders of TEAD under development by Beactica for treatment of cancer.Under the agreement, NCATS will gain access to proprietary targeted degraders of TEAD from Beactica to evaluate their efficacy in disease-relevant

Beactica Therapeutics strengthens its preclinical development team

Beactica Therapeutics AB, the Swedish precision oncology company, today announced two appointments to its preclinical development team. Dr Anneli Hällgren will lead the preclinical development and Dr Carl Magnus Andersson will lead the CMC activities. The appointments are made in preparation for IND-enabling studies of preclinical candidate BEA‑17, a novel small molecule cancer immunotherapeutic agent under development by Beactica.Dr Anneli Hällgren has more than 25 years of experience from drug development within several therapeutic areas and with emphasis on preclinical development

Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate

Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers.BEA-17 is a first-in-class small molecule which has shown promising potentiation of immune-modulating treatments in preclinical models of several cancer forms. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM), the most aggressive form of brain tumour. With the

Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities

Beactica Therapeutics AB, the Swedish precision oncology company, today announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors. The appointment marks another step in Beactica’s strategic plan to become a clinical-stage company. Jarl Ulf Jungnelius M.D. is a licensed medical practitioner and a board-certified oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. He worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid

Beactica Therapeutics to present breakthrough in YAP–TEAD programme at the Hippo Pathway Drug Development Summit 2023

Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP–TEAD programme has been selected for an oral presentation at the 2[nd] Hippo Pathway Targeted Drug Development Summit 2023. The conference will take place on May 23–35, 2023, in Boston, Massachusetts.Dr Peter Brandt, Head of Chemistry, will present a talk entitled Specific Degraders of TEADs Based on Interface 3 Binding on Thursday May 25, 2023, at 2:00 – 2:30 PM in the Boston Park Plaza. The presentation will showcase a breakthrough in the development of novel cell-active targeted degraders of

Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration

Uppsala, Sweden and Seoul, South Korea Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on research and development of novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme.The LSD1 programme includes BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. The current lead indication for BEA-17

Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma

PRESS RELEASE Uppsala, Sweden – 1 February 2023   Beactica Therapeutics AB, the Swedish precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma (GBM). BEA-17 is a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. Overexpression of LSD1 has been implicated in the pathogenesis of a variety of cancers, including GBM. There are currently no approved therapies for GBM that target this enzyme. “The FDA’s decision

Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration

Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on developing novel candidate compounds against multiple cancer targets of mutual interest. The partnership has been productive, and multiple compound classes are now in various stages of lead generation and optimization.  As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global

Beactica Therapeutics appoints Head of Chemistry and two new members to its Board of Directors to strengthen its strategic focus on cancer

Beactica Therapeutics AB, the Swedish drug discovery & development company, today announced the appointment of a Head of Chemistry and two new members of the Board. The appointments are made to strengthen the organisation as the company further sharpens its strategic focus on developing novel cancer therapeutics.Dr Peter Brandt is appointed Head of Chemistry and brings with him more than 20 years of industrial experience in drug discovery & development. Before joining Beactica, Peter has held leading positions at AstraZeneca, the Department of Medicinal Chemistry at Uppsala University, KDev

Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical development of novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization. Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further

Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer

Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration agreement. The two parties will work together in a project aimed at inhibiting WRN helicase, a protein with significant therapeutic potential for cancers with microsatellite instability. The collaboration will leverage core capabilities of each partner and build on the work of Professor John Rouse, on the control of chromosome stability and DNA repair in cancer. Beactica will contribute key

Dong-A ST and Beactica Therapeutics achieve key milestone in their collaboration to develop new cancer treatments

Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish drug discovery company, today announced that a lead compound meeting certain pre-defined criteria has been selected in their collaborative research programme aimed at developing first-in-class protein–protein interaction inhibitors for a target of therapeutic importance in cancer and other diseases. The milestone transition provides Dong-A ST with exclusive global rights for further development and commercialization of products based on, or derived from, the lead compound. In

Beactica Therapeutics participates in innovative training network on targeted protein degradation

PRESS RELEASE Uppsala, Sweden – 30 October 2019Beactica Therapeutics, the Swedish drug discovery company, today announced its participation in a Marie Skłodowska-Curie Innovative Training Network (ITN) called UbiMotif. The ITN is funded with EUR 4.1 million under the European Commission's Horizon 2020 programme and aims to deliver 15 skilled early-stage researchers in the area of targeted protein degradation, an emerging field predicted to revolutionize how “undruggable” proteins can be targeted in diseases such as cancer and neurodegeneration. UbiMotif will focus on identification,

Beactica Therapeutics appoints several high-profile people to strengthen its strategic focus on drug discovery

Uppsala, SwedenBeactica Therapeutics, the Swedish drug discovery company, today announced the appointment of a Head of Preclinical Development, two new members of the Board, and a clinical advisor. The appointments are made to strengthen the organisation as the company sharpens its strategic focus on drug discovery and development.  Vendela Parrow, PhD is appointed to Head of Preclinical Development. She brings with her an extensive experience in preclinical and clinical development from key positions at Akinion Pharmaceuticals, Axelar and Pharmacia Biovitrum. Vendela was a Co-founder,

Dong-A ST and Beactica expand their research and licence agreement to develop new cancer treatments

Seoul, South Korea and Uppsala, Sweden – 12 March 2019Dong-A ST Co., Ltd. (170900: Korea SE), the Korean pharmaceutical company, and Beactica AB, the Swedish drug discovery company, today announced an expansion of their research and licensing agreement. The collaboration – which was initiated in October 2016 – is now expanded with an aim to jointly identify and develop novel small molecules targeting a protein–protein interaction of therapeutic relevance for immuno-oncology. The partnership further builds on Beactica's unique early-stage lead generation capabilities and DONG-A ST's

Beactica closes financing round to accelerate its pipeline of novel cancer therapeutics

Uppsala, Sweden – 28 August 2018Beactica , the Swedish drug discovery company, today announced the completion of its latest financing round, providing significant funds that will be used to advance the Company’s internal pipeline of discovery-stage oncology programmes. The financing round was Beactica’s most successful to date, being almost 60% oversubscribed. Over one third of the investors were new to Beactica, raising the majority of the funds. The remainder was provided by several existing shareholders, including ALMI Invest and UNIONEN. The funds raised will

Beactica signs three-year extension agreement with Sanofi

Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced that it has signed a three-year extension of its master services agreement with Sanofi. The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins. As part of the collaboration, Beactica scientists have supported Sanofi with analysis of the interaction kinetics between insulin analogues and their two binding sites on the full-length insulin receptor. Results

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe